1. Computed tomography guided interstitial percutaneous high-dose-rate brachytherapy in the management of lung malignancies. A review of the literature
- Author
-
Konstantinos Ferentinos, Alexis Vrachimis, Nikolaos Zamboglou, Efstratios Karagiannis, Iosif Strouthos, and P Doolan
- Subjects
medicine.medical_specialty ,Percutaneous ,Lung Neoplasms ,medicine.medical_treatment ,Brachytherapy ,Computed tomography ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Lung cancer ,Lung ,medicine.diagnostic_test ,business.industry ,Interstitial brachytherapy ,Treatment options ,Radiotherapy Dosage ,medicine.disease ,High-Dose Rate Brachytherapy ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Radiology ,business ,Tomography, X-Ray Computed ,Follow-Up Studies - Abstract
A growing number of patients with lung cancer are not amenable to surgery due to their age or comorbidities. For this reason, local ablative techniques have gained increasing interest recently in the management of inoperable lung tumors. High-dose-rate percutaneous interstitial brachytherapy, performed under CT-guidance, is a newer form of brachytherapy and is a highly conformal radiotherapy technique. The aim of this study was to describe this method and review the existing literature. Eight articles comprising 234 patients reported toxicity and clinical outcome. The follow-up ranged from 6 to 28 months. Diverse fractionation schemes were reported, with 20 Gy in a single fraction being the most frequently utilized. Toxicity was limited; major pneumothoraces occurred after only 8% of the interventions. Local control rates at one year ranged between 37% and 91%. In conclusion, high-dose-rate percutaneous interstitial brachytherapy is a safe, fast, and efficient treatment option for inoperable lung tumors.
- Published
- 2020